- Home
- CNTB vs SGMO Comparison
CNTB vs SGMO Comparison
Compare CNTB & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | SGMO |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 141.2M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CNTB | SGMO |
|---|---|---|
| Price | $3.02 | $0.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $8.50 | $5.75 |
| AVG Volume (30 Days) | 110.9K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.22 | 66.89 |
| EPS | N/A | ★ N/A |
| Revenue | $26,033,000.00 | ★ $36,567,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | $24,617.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $0.51 | $0.35 |
| 52 Week High | $3.28 | $1.04 |
Technical Indicators
Market Signals| Indicator | CNTB | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 62.63 | 50.42 |
| Support Level | $2.30 | $0.36 |
| Resistance Level | $3.23 | $0.56 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 92.17 | 26.77 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.